REMARKABLE
reMarkable today announced its next-generation paper tablet, reMarkable 2. The breakthrough device for note-taking and reviewing documents without distractions comes from the Norwegian developers behind the original paper tablet, which broke pre-order records during its 2017 launch.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200317005154/en/
reMarkable 2 is available for pre-order from reMarkable.com for €399, and is set to ship in June 2020. The limited-time launch offer will include a Marker and Folio.
At 0.19 in/4.7 mm thick, reMarkable 2 is the world’s thinnest tablet. Armed with weeks of battery life, and the breakthrough second-generation CANVAS display partially powered by E Ink technology, reMarkable 2 is the most paper-like digital device the industry has ever seen.
“reMarkable 2 supports our design philosophy of helping people think better through powerful technology,” said Magnus Wanberg, CEO of reMarkable. “Our latest tablet is paper-thin and our innovations in display technology make it so much like writing on paper that it’s hard to tell the difference.”
Inspired by paper, reMarkable 2 is a tool for note-taking, reading, and annotating documents without built-in distractions. “Today’s world is a frenzied place of ever-evolving technology that increasingly demands more of our time and attention. reMarkable 2 is a step in a more human-friendly direction. It’s designed to help people think,” said Wanberg.
The company has spent the last six years developing and perfecting its breakthrough paper tablet to deliver a realistic paper experience that supports improved focus and better thinking, while still maintaining a connection to the digital world.
reMarkable 2 features the ability to convert handwritten notes into text, along with options for organizing, sharing, annotating and searching documents. Among a host of other digital features, reMarkable’s cloud service makes content accessible through multi-platform companion apps for desktop and mobile. Its feature set is aimed at anyone who likes writing by hand, but wants to be able to reuse their work in their digital workflow.
At launch, reMarkable 2 will be accompanied by a Google Chrome plug-in that will allow users to read clean, reformatted web articles on their paper tablet without distractions.
Innovations in ultra-thin, high-friction surface materials and a completely redesigned, second-generation CANVAS display, make reMarkable 2 an unprecedented digital paper device. Millions of physical ink particles lift to the display’s surface, working in tandem with the high precision Marker to deliver exceptional paper-like accuracy.
A range of accessories to compliment reMarkable 2
All accessories are either included in their respective launch bundles, available as a bundle upgrade, or can be purchased separately later in the year when the pre-order finishes.
Markers:
reMarkable 2 will launch with two different Markers, both of which attach magnetically to the right side of the paper tablet:
Marker - €59 (included in pre-order)
Marker Plus (includes built-in eraser in the top end) - €99
Folios
: Folio and Book Folio have been created with function and style in mind. They’re both made from fine materials and designed to fit reMarkable 2 perfectly.
Folio - €79 - The original sleeve for reMarkable 2 (included in the first part of pre-order)
Book Folio - from €99 - Lets you keep your reMarkable 2 in its cover while working. Attaches magnetically to reMarkable 2
About reMarkable
Based in Oslo, Norway, reMarkable is the leading innovator within the paper tablet category, developing breakthrough digital paper tablets for note-taking, reading, and reviewing documents. Its vision is to create human-friendly products to help people think better. For more information about reMarkable and its digital paper tablet, visit https://remarkable.com
YouTube: https://youtu.be/0dgXuStEm4U
Instagram: https://www.instagram.com/remarkable/
Facebook: https://www.facebook.com/remarkableAS
Twitter: https://twitter.com/remarkablepaper
#remarkablepaper
View source version on businesswire.com: https://www.businesswire.com/news/home/20200317005154/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom